By analyzing patients' genomic information, key mutations driving tumor growth can be identified, allowing for the selection of individualized, targeted therapies.[4] Moreover, single‐cell RNA‐seq enables the exploration of gene expression differences among various cell populations within the tumor, providing deeper insights into tumor heterogeneity and its response to treatment.[5] At the initial stage of the study, genomic analysis of osteosarcoma identified cyclin‐dependent kinases 4/6 (CDK4/6) inhibitor and poly ADP‐ribose polymerase (PARP) inhibitor as potential therapeutic agents. Here, CDK4 is linked to neoplasm.